Chess Study Revives Debate Over Cognition-Enhancing Drugs
JAMA doi:10.1001/JAMA:2017.8114, Lyon, J., 2017
Responding to Requests from Adult Patients for Neuroenhancements
Neurol 73:1406-1412, Larriviere,D.,et al, 2009
Primary Diffuse Leptomeningeal Melanocytosis, A Diagnoatic Conundrum
Neurol 101:e576-3580, Selvarajan,J.M.P.,et al, 2023
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Non-Alzheimers Dementia 3 Vascular Dementia
Lancet 386:1698-1706, OBrien, J.T. & Thomas, A., 2015
Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment
Neurol 70:2024-2035, Winblad,B.,et al, 2008
Outcome in Adult Low-Grade Glioma: The Impact of Prognostic Factors and Treatment
Neurol 69:1366-1373, Schiff,D.,et al, 2007
Transient Global Amnesia: Increasing Evidence of a Venous Etiology
Arch Neurol 63:1334-1336 ,1336, Menendez,M. &Rivera,M.M., 2006
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
The Utility of MRI in Suspected MS, Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 61:602-611,596, Frohman,E.M.,et al, 2003
Effect of Radiotherapy and Other Treatment-Related Factors on Mid-Term to Long-Term Cognitive Sequelae in Low-Grade Gliomas: A Comparative Study
Lancet 360:1361-1368, Klein,M.,et al, 2002
Brainstem Gliomas in Adults: Prognostic Factors and Classification
Brain 124:2528-2539, Guillamo,J.-S.,et al, 2001
Prethrombolysis Brain Imaging:Trends and Controversies
AJNR 18:1830-1834, Castillo,M., 1997